Short answer: Survodutide is Boehringer Ingelheim's investigational GLP-1 / glucagon receptor dual agonist, studied for obesity and for MASH / MASLD. Phase 3 (the SYNCHRONIZE program) reported roughly 16.6% mean body-weight reduction, and its glucagon arm gives it a distinctive liver-fat and visceral-fat research angle. It is investigational, not approved, and supplied here research use only.
The next generation of obesity therapies is increasingly focused on targeting multiple metabolic pathways. One of the most notable examples is Survodutide, an investigational therapy developed by Boehringer Ingelheim that combines GLP-1 receptor activity with glucagon receptor activity.
While many obesity programs focus primarily on weight reduction, Survodutide has gained attention because of its potential relevance to obesity, metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and visceral-fat reduction. This article examines the science, clinical-development program, and research significance of Survodutide.
Plain-English summary. Survodutide is a research-stage molecule, not a medicine you can buy or use. Everything below describes published preclinical and clinical-trial findings for laboratory and educational context. New-U supplies research-use-only material and does not provide dosing, medical, or human-use guidance.
Survodutide is an investigational dual agonist designed to activate:
Researchers believe this combination may influence energy expenditure, appetite regulation, body-weight reduction, liver-fat metabolism, and metabolic health markers. The compound represents one of the most advanced glucagon-containing obesity therapies currently in development.
Glucagon is often associated with blood-glucose regulation, but research increasingly suggests broader metabolic effects. Scientists are investigating glucagon-related mechanisms for potential influence on:
Combining glucagon activity with GLP-1 activation may create a complementary metabolic profile.
MASH has emerged as one of the most significant areas of metabolic research. The condition involves excess liver fat, inflammation, progressive liver damage, and metabolic dysfunction. Researchers estimate that increasing obesity prevalence may continue driving MASH-related healthcare challenges globally. Because obesity and liver disease are closely connected, therapies capable of addressing both areas attract significant attention.
Survodutide is being evaluated through the SYNCHRONIZE clinical-development program. Research objectives include weight reduction, liver-fat assessment, metabolic outcomes, and long-term safety evaluation. The program reflects growing industry interest in the overlap between obesity and liver disease.
Reported Phase 3 findings demonstrated approximately:
While efficacy appears lower than some leading incretin candidates, researchers continue to evaluate the broader metabolic profile.
One of the most important differentiators is Survodutide's liver-focused research. Investigators have reported reductions in liver fat, improvements in metabolic markers, and changes in visceral-fat measurements. These findings contribute to interest in Survodutide's potential role within obesity and liver-disease research programs.
Survodutide differs from several competing therapies in the next-generation obesity field:
| Candidate | Primary biology |
|---|---|
| MariTide | GLP-1 + GIP antagonism |
| CagriSema | GLP-1 + amylin |
| Amycretin | GLP-1 + amylin |
| Petrelintide | Amylin |
| Survodutide | GLP-1 + glucagon |
This diversity highlights how obesity research is moving beyond a single biological pathway.
Survodutide represents a unique approach within next-generation obesity research. By combining GLP-1 and glucagon biology while simultaneously targeting weight and liver-related endpoints, the program occupies an important position in the evolving metabolic-research landscape.
What is survodutide?
Boehringer Ingelheim's investigational GLP-1 / glucagon receptor dual agonist, studied for obesity and MASH. Investigational, not approved; research use only.
Why is it studied for MASH?
Its glucagon arm is researched for liver-fat metabolism and energy expenditure, so it is evaluated against both weight and liver endpoints - unlike weight-only programs.
How much weight loss did it show?
Reported Phase 3 data described ~16.6% mean body-weight reduction with meaningful placebo-adjusted effects.
Is survodutide FDA approved?
No - it is investigational (SYNCHRONIZE program). Material supplied as survodutide is research use only, not for human consumption.
Research use disclaimer. Educational content only. No medical advice, treatment guidance, dosing information, or human-use instructions are provided.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog